John W. Kitchens, MD, discusses patient selection for geographic atrophy treatment, counseling approaches, and emerging ...
A peer-reviewed study evaluating serial application of decellularized basement membrane (DBM) (Biovance Ocular; DefEYE) in patients with subclinical or Mackie Stage 1 neurotrophic keratitis (NK) found ...
Japan's Ministry of Health, Labour and Welfare (MHLW) granted orphan drug designation to gildeuretinol acetate (ALK-001; Alkeus Pharmaceuticals) for Stargardt disease, a status that unlocks ...
Zhang traced growing interest in home tonometry back to the COVID-19 pandemic, when clinicians needed new ways to track patie ...
Angela Y. Zhu, MD, of Bascom Palmer Eye Institute, explains how to distinguish eye allergy from vision-threatening VKC and ...
Dante Pieramici, MD, of California Retina Consultants, framed the sustained-delivery tyrosine kinase inhibitor (TKI) EYP-1901 ...
Jonathan Gloth, MD, explains how MK-8748's dual Tie2 agonist/VEGF inhibitor mechanism differs from VEGF blockade alone, and ...
Vitreoretinal specialist Dante Pieramici, MD, of California Retina Consultants breaks down the phase 3 COMO and CAPRI trials ...
The FDA has granted Avulux De Novo marketing authorization for its precision optical filter lens, creating the first FDA-recognized device classification for a lens targeting migraine-associated ...
Men who took tadalafil for lower urinary tract symptoms (LUTS) had a 22% higher risk of developing glaucoma than matched peers who did not use a phosphodiesterase type 5 inhibitor ...
A former US Navy flight surgeon turned three-time CMO, David J. Tanzer, MD, ABO, reflects on a career built at the pharma-clinic bridge.
Reem Amine, MD, discusses why clinic distance predicts loss to follow-up in geographic atrophy and shares one retention check practices can implement now. Amine’s study examined factors associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results